Market Size of Glaucoma Treatment Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 6.40 Billion |
| Market Size (2029) | USD 8.02 Billion |
| CAGR (2024 - 2029) | 4.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Glaucoma Treatment Market Analysis
The Glaucoma Treatment Market size is estimated at USD 6.40 billion in 2024, and is expected to reach USD 8.02 billion by 2029, growing at a CAGR of 4.60% during the forecast period (2024-2029).
The major factors for the growth of the glaucoma treatment market include the increasing prevalence of glaucoma, rising initiatives to increase awareness about glaucoma, and technological advancements in the field of ophthalmology.
Glaucoma is the second leading cause of blindness, globally. This generally happens due to raised intraocular tension. The main therapeutic goal is to lower the intraocular tension. This is done either by reducing the secretion of aqueous humor or increasing its drainage. Glaucoma has also been divided into an open angle (wide angle), chronic glaucoma and angle-closure (narrow-angle), and acute congestive glaucoma. Although the drugs of glaucoma reduce the symptoms, there is no complete cure for this condition. The drugs used for the treatment of glaucoma are segmented into beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, prostaglandin analogs, and combination medications.
According to WHO estimates, more than 60 million patients are suffering from glaucoma worldwide, as per 2019 statistics. According to the Glaucoma Research Foundation, in the United States, more than 120,000 patients are blind from glaucoma. Thus, owing to the rising cases of glaucoma the market is expected to witness high growth over the forecast period.
Glaucoma Treatment Industry Segmentation
As per the scope of this report, glaucoma treatment market covers the drugs used to reduce the secretion of aqueous humor or increasing its drainage. The market is segmented by indication, drug class, and geography.
| By Indication | |
| Open Angle Glaucoma | |
| Closed Angle Glaucoma | |
| Secondary Glaucoma | |
| Congenital Glaucoma | |
| Others |
| By Drug Class | |
| Prostaglandin Analogs | |
| Beta Blockers | |
| Alpha Agonist | |
| Carbonic Anhydrase Inhibitors | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Glaucoma Treatment Market Size Summary
The glaucoma treatment market is poised for significant growth, driven by the increasing prevalence of glaucoma and heightened awareness initiatives. Glaucoma, a leading cause of blindness globally, is primarily managed by lowering intraocular pressure through various therapeutic approaches. These include the use of beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, prostaglandin analogs, and combination medications. Technological advancements in ophthalmology further bolster market expansion. Prostaglandin analogs, in particular, are gaining traction due to their effectiveness in reducing intraocular pressure, especially in open-angle glaucoma, despite some associated side effects. The aging population, which is more susceptible to glaucoma, is expected to drive demand for these treatments, thereby enhancing market growth.
The United States is anticipated to lead the glaucoma treatment market, supported by a robust healthcare infrastructure and a significant number of glaucoma cases. The economic impact of glaucoma in the U.S. is substantial, with billions lost annually in direct costs and productivity. Awareness campaigns by various organizations are expected to further stimulate market growth. The market is characterized by consolidation, with a few major players such as AERIE PHARMACEUTICALS, INC., Allergan Plc, and Novartis AG dominating the landscape. These companies are pivotal in shaping the market dynamics through their innovative treatment offerings and strategic initiatives.
Glaucoma Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Glaucoma
-
1.2.2 Rising Initiatives to Increase Awareness about the Glaucoma
-
1.2.3 Technological Advancements in the Field of Ophthalmology
-
-
1.3 Market Restraints
-
1.3.1 Side Effects associated with the Products
-
1.3.2 Stringent Approval Process
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Indication
-
2.1.1 Open Angle Glaucoma
-
2.1.2 Closed Angle Glaucoma
-
2.1.3 Secondary Glaucoma
-
2.1.4 Congenital Glaucoma
-
2.1.5 Others
-
-
2.2 By Drug Class
-
2.2.1 Prostaglandin Analogs
-
2.2.2 Beta Blockers
-
2.2.3 Alpha Agonist
-
2.2.4 Carbonic Anhydrase Inhibitors
-
2.2.5 Others
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Glaucoma Treatment Market Size FAQs
How big is the Glaucoma Treatment Market?
The Glaucoma Treatment Market size is expected to reach USD 6.40 billion in 2024 and grow at a CAGR of 4.60% to reach USD 8.02 billion by 2029.
What is the current Glaucoma Treatment Market size?
In 2024, the Glaucoma Treatment Market size is expected to reach USD 6.40 billion.
